Neratinib is an oral small-molecule tyrosine kinase inhibitor of HER1, HER2, and HER4 with single-agent and combination activity in patients with metastatic HER2-positive breast cancer previously treated with trastuzumab [10, 16–18]. The gene discussed is ERBB2; the disease is breast carcinoma.